Literature DB >> 15489013

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

Petra Steinacker1, Brit Mollenhauer, Mirko Bibl, Lukas Cepek, Hermann Esselmann, Peter Brechlin, Piotr Lewczuk, Sigrid Poser, Hans A Kretzschmar, Jens Wiltfang, Claudia Trenkwalder, Markus Otto.   

Abstract

The diagnosis of neurodegenerative diseases with dementias requires several different test approaches and often remains uncertain. Using a proteomic approach it was shown in nine patients that heart fatty acid binding protein (H-FABP) might be a biomarker for Creutzfeldt-Jakob disease (CJD). The aim of our study was to evaluate whether H-FABP is a biomarker for the differential diagnosis of dementias. Therefore we measured H-FABP in cerebrospinal fluid (CSF) and serum of patients having CJD, dementia with Lewy-bodies (DLB), Alzheimer's disease (AD) and in non-demented control (NDC) patients. H-FABP levels in CSF and serum of CJD patients are increased compared to non-demented controls. Levels of H-FABP were significantly higher in CJD patients compared to AD and DLB in CSF. However, discrimination between CJD and AD was not possible in serum. Interestingly, highest levels of H-FABP were found in serum of DLB patients. Our results suggest that H-FABP might be a useful biomarker for the differentiation between the dementias examined if levels in CSF and serum are determined in parallel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489013     DOI: 10.1016/j.neulet.2004.07.061

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

1.  Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Eve Pickering; Max Kuhn; Yu Chen; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-03-16       Impact factor: 17.088

Review 2.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel; Henrik Zetterberg
Journal:  Neuropsychopharmacology       Date:  2013-06-25       Impact factor: 7.853

Review 4.  Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-07-22       Impact factor: 17.088

5.  Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the CSF of CJD patients.

Authors:  Yuki Matsui; Katsuya Satoh; Kazuo Mutsukura; Takuya Watanabe; Noriyuki Nishida; Hideo Matsuda; Masaichi Sugino; Susumu Shirabe; Katsumi Eguchi; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2010-05-25       Impact factor: 5.046

Review 6.  Application of "Omics" Technologies for Diagnosis and Pathogenesis of Neurological Infections.

Authors:  Farshid Noorbakhsh; Atefeh Aminian; Christopher Power
Journal:  Curr Neurol Neurosci Rep       Date:  2015-09       Impact factor: 5.081

7.  Genomic and post-genomic analyses of human prion diseases.

Authors:  Maurizio Pocchiari; Anna Poleggi; Serena Principe; Silvia Graziano; Franco Cardone
Journal:  Genome Med       Date:  2009-06-22       Impact factor: 11.117

8.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-17       Impact factor: 5.270

9.  Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis.

Authors:  K Wada-Isoe; K Michio; K Imamura; K Nakaso; M Kusumi; H Kowa; K Nakashima
Journal:  J Neural Transm (Vienna)       Date:  2007-08-10       Impact factor: 3.575

10.  Neurochemical biomarkers in Alzheimer's disease and related disorders.

Authors:  Mirko Bibl; Hermann Esselmann; Jens Wiltfang
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.